[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-heart-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-heart-disease":25},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,44,0,25,[9,40,66,97,127,157,182,202,224,250,274,300,322,351,376,396,424,450,475,507,532,559,576,614,638],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100644344","construction-of-a-prospective-cohort-database-for-the-perioperative-period-of-cardiac-surgery-100644344",false,"NCT07662317","Construction of a Prospective Cohort Database for the Perioperative Period of Cardiac Surgery","Inclusion Criteria:\n\n* Patients undergoing cardiac surgery from May 1, 2026 to December 31, 2031\n\nExclusion Criteria:\n\n* Refusal to provide informed consent","ALL",{"count":18,"type":19},10000,"ESTIMATED","OBSERVATIONAL","Cardiovascular disease (CVD) is the leading cause of global morbidity and mortality, with its prevalence increasing significantly from 1990 to 2019. Establishing a comprehensive cardiac surgery database is crucial for exploring perioperative prognostic factors and improving clinical outcomes.\n\nThis muti-center, prospective observational study aims to construct a prospective cohort database for perioperative cardiac surgery. We plan to enroll adult patients who undergo cardiac surgery with cardiopulmonary bypass at the Second Affiliated Hospital of Zhejiang University and other hospitals from May 1, 2026 to December 31, 2031. Multi-dimensional perioperative data, including laboratory tests, hemodynamics, intraoperative echocardiography, and perioperative medications, will be collected and integrated, along with epidemiological data, clinical diagnosis and treatment information, multimodal data, and follow-up outcomes. An interconnected big data sharing platform will also be built.\n\nThis database will provide a valuable resource for multi-level researches such as perioperative risk assessment, individualized prevention, precise diagnosis and treatment, and therapeutic efficacy monitoring. It will also help optimize surgical and perioperative management, improve the quality of cardiac surgery, and provide evidence for the refinement of China's healthcare system, ultimately enhancing perioperative safety and rehabilitation efficiency of patients.",[23,24,25,26],"Valve Heart Disease","Coronary Artery Disease","Coronary Heart Disease","Aortic Diseases","RECRUITING","2026-06-22",{"date":30,"type":31},"2026-06-23","ACTUAL",{"date":33,"type":19},"2026-06-25",{"date":35,"type":19},"2032-05-31",{"name":37,"class":38},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",1,{"id":41,"slug":42,"hasResults":12,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":39},"100641153","modifiable-risk-factors-for-cognitive-dysfunction-in-patients-with-coronary-heart-disease-100641153","NCT07657624","Modifiable Risk Factors for Cognitive Dysfunction in Patients With Coronary Heart Disease","Association Between Modifiable Risk Factors and Cognitive Function in Patients With Coronary Heart Disease","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Diagnosis of coronary heart disease (meeting at least one of the following):\n\n   * Coronary angiography or coronary CTA showing ≥50% stenosis in ≥1 major coronary artery;\n   * Established diagnosis of coronary heart disease with prior medical, interventional, or surgical treatment;\n   * Objective evidence of myocardial ischemia or typical clinical symptoms\n3. Completion of standardized neuropsychological assessment during hospitalization\n4. Completion of metabolic marker evaluation (fasting glucose, insulin, HbA1c, etc.) and agreement to undergo relevant imaging and functional assessments\n5. Provision of signed written informed consent\n\nExclusion Criteria:\n\n1. Previously diagnosed dementia.\n2. History of stroke, cerebral hemorrhage, or other central nervous system diseases known to cause cognitive impairment.\n3. Severe psychiatric disorders (e.g., schizophrenia, bipolar disorder).\n4. Pregnancy or breastfeeding.","18 Years",{"count":49,"type":19},2352,"This prospective observational study aims to investigate the association between risk factors and cognitive function in patients with coronary heart disease (CHD), and to explore the underlying mechanisms involving metabolic parameters and multimodal imaging features. A total of 2,352 participants will be enrolled from Beijing Anzhen Hospital, Capital Medical University, China. Eligible participants are adults (≥18 years) with confirmed CHD who undergo systematic neuropsychological assessment during hospitalization. Comprehensive assessments include cognitive function tests (MMSE, MoCA, BCAT, AD8), metabolic evaluations (fasting glucose, insulin, HbA1c, ceramides), coronary computed tomography angiography (CCTA), cardiac magnetic resonance (CMR), sleep respiratory monitoring, and frailty and psychological assessments.The primary outcome is cognitive impairment. The study will identify potential risk factors and provide insights into early identification and personalized intervention strategies for cognitive decline in CHD patients.",[25,52],"Cognitive Impairment, Mild",[54,55,25],"Risk Factors","Cognitive Impairment","NOT_YET_RECRUITING","2026-06-15",{"date":59,"type":31},"2026-06-18",{"date":61,"type":19},"2026-06-30",{"date":63,"type":19},"2031-05-01",{"name":65,"class":38},"Beijing Anzhen Hospital",{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":39},"100641299","phase-4-effect-of-mazdutide-on-coronary-plaque-in-patients-with-coronary-atherosclerosis-and-overweight-or-obesity-100641299","NCT07657676","Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity","Effect of Mazdutide on Coronary Plaque Progression in Patients With Coronary Atherosclerosis and Overweight or Obesity: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. BMI ≥ 28 kg\u002Fm2 or BMI≥ 24kg\u002Fm2 with at least one of the following conditions: dyslipidemia, metabolic associated fatty liver disease, hypertension, prediabetes, type 2 diabetes mellitus, or obesity-related obstructive sleep apnea syndrome (at screening or within 6 months prior to screening).\n3. Coronary stenosis 30-70% confirmed by CAG or CCTA\n4. Signed informed consent\n5. Willing to comply with follow-up\n\nExclusion Criteria:\n\n1. History or evidence of the following :\n\n   1. A history of severe hypoglycemia, or recurrent symptomatic hypoglycemia (≥2 episodes) within the past six months\n   2. Severe heart disease as determined by the investigator, including coronary artery disease that has undergone or is planned for coronary artery bypass grafting or percutaneous coronary intervention, valvular heart disease requiring valve repair or replacement, heart transplantation, severe heart failure (NYHA III-IV) or cardiogenic shock, or a known history of left ventricular ejection fraction ≤30%\n   3. A hemorrhagic\u002Fischemic stroke or transient ischemic attack within six months prior to screening\n   4. A history of acute or chronic pancreatitis, gallbladder\u002Fbile duct disease, or pancreatic injury\n   5. Presence of severe diseases such as malignant tumors, lymphoma, liver cirrhosis, HIV-positive status, etc., with an expected survival of less than 2 years\n   6. Contraindications to GLP-1\u002FGCG dual receptor agonists, such as hypersensitivity or severe intolerance\n   7. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2\n2. Use of the following medications or treatments prior to screening :\n\n   1. Use of weight-affecting medications (e.g., systemic steroids, tricyclic antidepressants, psychiatric\u002Fsedative medications, etc.) within three months prior to screening\n   2. Use of GLP-1 RA or GIP\u002FGLP-1 RA (exposure to investigational drugs) within three months prior to screening\n   3. Participation in other clinical trials (exposure to investigational drugs) within three months prior to screening\n   4. Known clinically significant abnormal gastric emptying or current use of medications that directly affect gastrointestinal motility\n3. Laboratory test results meeting any of the following criteria at screening (repeat testing within one week is permitted if there is a clear reason, and the reason for retesting must be documented by the investigator)\n\n   1. Serum calcitonin ≥50 ng\u002FL (pg\u002FmL)\n   2. ALT\u002FAST \\>3.0 × ULN\n   3. eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²\n   4. Abnormal thyroid function (TSH \\>6 mIU\u002FL or \\\u003C0.4 mIU\u002FL)\n4. Pregnancy, planned pregnancy, or breastfeeding\n5. Contraindications to CCTA, including severe allergy to iodine contrast agents, presence of cardiac implantable electronic devices or other metal implants that may affect image analysis\n6. Inability to complete the study or comply with study requirements as determined by the investigator Exclusion criteria for the PET-CT substudy: All exclusion criteria of the main study, as well as contraindications to PET-CT examination",{"count":74,"type":19},116,"INTERVENTIONAL",[77],"PHASE4","This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the effect of mazdutide, a dual GLP-1\u002FGCG receptor agonist, on coronary plaque progression assessed by coronary computed tomography angiography (CCTA) in patients with coronary atherosclerosis and overweight or obesity. The primary endpoint is the change in total non-calcified plaque volume (NCPV) from baseline to week 52. Secondary endpoints include changes in pericoronary adipose tissue inflammation (fat attenuation index, FAI), plaque composition, metabolic parameters, inflammatory biomarkers, and clinical outcomes. A substudy will include 18F-NAF PET\u002FCT imaging.",[80,25],"Obesity & Overweight",[82,83,84,85,86,87,25],"GLP-1RA","CCTA","Mazdutide","Obesity","Plaque","Overweight","2026-06-14",{"date":59,"type":31},{"date":91,"type":19},"2026-05-25",{"date":93,"type":19},"2028-02-28",{"name":95,"class":96},"China National Center for Cardiovascular Diseases","OTHER_GOV",{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":75,"phases":106,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":39},"100605681","ctca-prior-to-invasive-angiography-in-post-bypass-patients-bypass-ctca-2-100605681","NCT07165678","CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2)","A Multi-Centre, Randomised Trial Assessing the Value of Computed Tomography Coronary Angiography Prior to Invasive Coronary Angiography in Patients With Previous Coronary Artery Bypass Grafts in Reducing Cardiac Events","Inclusion Criteria:\n\n* Aged ≥18\n* Previous coronary artery bypass grafting (CABG)\n* An indication for coronary angiography\n\n  * Angina\n  * Ischaemia on perfusion imaging\n  * Acute coronary syndrome\n* Patients are able and willing to give their written informed consent\n\nExclusion Criteria:\n\n* Subjects presenting with ST segment myocardial infarction within window for primary PCI\n* Patients considered unsuitable to participate by the research team (e.g. due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures)\n* Life expectancy less than 1 year",{"count":105,"type":19},1000,[107],"NA","The goal of this clinical trial is to evaluate whether a coronary computed tomography angiography (CTCA)-guided strategy can reduce the risk of death, heart attack, stroke, and hospital admissions in patients experiencing angina or myocardial infarction following coronary artery bypass graft (CABG) surgery. The main questions it aims to answer are:\n\n* Can CTCA reduce major adverse cardiovascular events compared to standard invasive coronary angiography?\n* Is CTCA a cost-effective and safer alternative that improves patient quality of life? Researchers will compare outcomes between patients receiving CTCA prior to angiography and those undergoing standard angiography alone to determine if CTCA improves clinical outcomes and procedural safety.\n\nParticipants will:\n\n* Be randomly assigned to either CTCA-guided care or standard angiography\n* Undergo coronary imaging and follow-up assessments\n* Complete questionnaires on quality of life and healthcare resource use",[25],[111,112,24,113,114,115,116,117],"Coronary Artery Bypass Graft","Angina","CABG","percutaneous coronary intervention","coronary angiograms","Computerised Tomography Coronary Angiography","CTCA","2026-06-03",{"date":120,"type":31},"2026-06-05",{"date":122,"type":31},"2026-04-16",{"date":124,"type":19},"2029-07-31",{"name":126,"class":38},"Queen Mary University of London",{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":135,"sex":16,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":4},"100612974","rapid-engagement-for-solutions-to-population-and-outcomes-through-networked-dialogue-for-coronary-heart-disease-100612974","NCT07260552","Rapid Engagement for Solutions to Population and Outcomes Through Networked Dialogue for Coronary Heart Disease","Rapid Engagement for Solutions to Population and Outcomes Through Networked Dialogue (RESPOND) to Coronary Heart Disease","RESPOND","Inclusion Criteria:\n\n* Adults aged 40-69 years of age\n* No prior history of coronary heart disease\n* No prior use of statin medication\n* Has primary care provider\n\nExclusion Criteria:\n\n* Prior history of coronary heart disease\n* current use of statin medication",true,"40 Years","69 Years",{"count":139,"type":19},200,"Cardiometabolic diseases are major causes of morbidity and mortality in the state of Wisconsin and are expected to pose an increasing burden over the next few decades. A crucial initial step in preventing or delaying the onset of these diseases is to assess disease risk at the individual level. However, the accuracy of risk prediction of disease events based on conventional risk factors remains modest. Incorporating a polygenic risk score (PRS) into risk equations improves risk prediction but there is uncertainty about how best to integrate PRSs into primary care settings, given the lack of familiarity with PRSs among patients and providers. Probabilistic estimates for risks of cardiometabolic diseases may be misunderstood, and genetic risk assessment may not be trusted by those in low resource rural or inner-city settings. The potential for using PRSs to refine disease risk estimates has led to numerous studies to assess their clinical utility; however, the vast majority have been conducted in tertiary academic medical centers, raising concern that communities with diminished access to care could be left behind. The study team will investigate how the use of PRSs for such diseases influences health outcomes in rural and inner-city settings. The study team will leverage prior experience in conducting the MIGENES randomized clinical trial (RCT) of disclosing polygenic risk of CHD in a preventive cardiology setting of an academic center. In the proposed study, the investigators will conduct a pragmatic RCT to extend the investigation to 'real-world' settings of primary care clinics in a rural medical center and an urban Federally Qualified Health Center (FQHC). The investigators will engage a Community Advisory Board (CAB) through focus groups to gather feedback on implementing PRS-guided screening, related medical and lifestyle interventions, and public health strategies to reduce CHD risk. Feedback will inform provider education, targeted outreach to Wisconsin residents, and identification of barriers to adoption. The study team will also assess primary care physicians' and patients' familiarity with polygenic risk, their attitudes toward PRS testing, and intended actions based on results, comparing responses across rural and urban settings. The 10-yr risk of CHD will be estimated based on pooled cohort equations (PCE). Participants will view a video describing how cardiovascular risk was estimated and how lifestyle changes and drug therapy could reduce such risk and, in those randomized to receive PRS, the probabilistic nature of genetic risk. Patients will then see their PCP to review the 10-yr CHD risk estimate and engage in shared decision-making regarding statin therapy. Patient and clinician understanding of polygenic risk information will be assessed, as well as health-related and behavioral outcomes.",[25],[143,144,145,146,147],"precision medicine","polygenic risk score","rural","urban","community","2026-04-28",{"date":150,"type":31},"2026-05-04",{"date":152,"type":19},"2027-06-01",{"date":154,"type":19},"2031-01-01",{"name":156,"class":38},"Medical College of Wisconsin",{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":75,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":39},"100635176","phase-4-use-dexmedetomidine-to-protect-myocardial-injury-evaluation-100635176","NCT07549282","Use Dexmedetomidine To Protect Myocardial Injury Evaluation","Effects of Preoperative Intranasal Dexmedetomidine on Perioperative Myocardial Injury and Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention: A Prospective, Randomized Controlled Trial","UDOPIE","Inclusion Criteria:\n\n* 18 years ≤ age ≤ 85 years;\n* Patients scheduled to undergo elective coronary angiography or percutaneous coronary intervention (PCI);\n* Classified as American Society of Anesthesiologists (ASA) physical status I-III (ranging from patients with mild systemic disease to those with more severe systemic disease that limits normal physical activity but who remain able to perform light daily tasks);\n* Informed consent obtained.\n\nExclusion Criteria:\n\n* Allergy or contraindication to dexmedetomidine, such as severe bradycardia (resting heart rate \\\u003C50 beats\u002Fmin), sick sinus syndrome, second-degree or higher atrioventricular block without a pacemaker;\n* Severe cardiac dysfunction (left ventricular ejection fraction \\\u003C35% or New York Heart Association functional class III-IV), cardiogenic shock, or hemodynamically unstable patients;\n* Uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg) or hypotension (systolic blood pressure \\\u003C90 mmHg);\n* Sleep apnea-hypopnea syndrome or Body Mass Index \\>30 kg\u002Fm²;\n* Use of alpha-2 adrenergic receptor agonists (e.g., clonidine) or antagonists, or tricyclic antidepressants, which may affect the action of the study drug, within 1 month before the procedure;\n* Language, visual, or hearing impairment that may affect cognitive assessment;\n* Hepatic or renal insufficiency (Alanine Aminotransferase\u002FAspartate Aminotransferase\u002FCreatinine \\>3 times the upper limit of normal);\n* Anatomical abnormalities of the nasal cavity affecting intranasal drug administration;\n* Pregnant or breastfeeding women.","85 Years",{"count":167,"type":19},1800,[77],"The goal of this clinical trial is to learn if preoperative intranasal dexmedetomidine works to reduce perioperative myocardial injury and myocardial infarction in patients undergoing elective percutaneous coronary intervention (PCI). It will also learn about the safety of intranasal dexmedetomidine. The main questions it aims to answer are:\n\nDoes preoperative intranasal dexmedetomidine lower the incidence of perioperative myocardial injury and myocardial infarction after PCI? Does intranasal dexmedetomidine cause safety concerns in patients undergoing PCI? Researchers will compare intranasal dexmedetomidine to a placebo (a look-alike substance that contains no drug) to see if intranasal dexmedetomidine works to protect the heart during PCI.\n\nParticipants will:\n\nReceive either intranasal dexmedetomidine (100 μg) or a placebo (normal saline) 15 minutes before the PCI procedure Undergo blood tests to measure cardiac troponin levels before and after the procedure Be followed for up to 30 days after the procedure to record any heart-related events or side effects",[25,171,172,173],"Myocardial Injury","Myocardial Infarction","Dexmedetomidine","2026-04-17",{"date":176,"type":31},"2026-04-24",{"date":178,"type":19},"2026-04",{"date":180,"type":19},"2028-04",{"name":37,"class":38},{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":75,"phases":190,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":39},"100610689","a-study-evaluating-the-vascular-healing-and-neointimal-transformation-at-1-month-after-implantation-of-biofreedom-drug-coated-stents-and-the-xience-drug-eluting-stent-system-in-patients-with-acute-coronary-syndrome-and-high-bleeding-risk-using-optical-coherence-tomography-100610689","NCT07230847","A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug-coated Stents and the Xience Drug-eluting Stent System in Patients With Acute Coronary Syndrome and High Bleeding Risk Using Optical Coherence Tomography","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Male or non-pregnant female\n3. Acute coronary syndrome (ACS) patients requiring percutaneous coronary intervention (PCI)\n4. No contraindications for coronary artery bypass grafting (CABG)\n5. High bleeding risk (HBR) patients per ARC-HBR definition (meeting ≥1 major or 2 minor criteria):\n\n   Major Criteria:\n   * Expected long-term oral anticoagulation\n   * Severe\u002Fend-stage chronic kidney disease (eGFR \\\u003C30 mL\u002Fmin)\n   * Moderate\u002Fsevere anemia (Hb \\\u003C110 g\u002FL)\n   * Spontaneous bleeding requiring hospitalization\u002Ftransfusion within 6 months (or recurrent)\n   * Chronic bleeding diathesis\n   * Moderate\u002Fsevere thrombocytopenia pre-PCI (platelet count \\\u003C100×10⁹\u002FL)\n   * Liver cirrhosis with portal hypertension\n   * Active malignancy in past 12 months (excluding non-melanoma skin cancer; defined as diagnosis\u002Ftreatment within 12 months)\n   * History of spontaneous intracranial hemorrhage\n   * Traumatic intracranial hemorrhage within 12 months\n   * Known cerebral arteriovenous malformation\n   * Moderate\u002Fsevere ischemic stroke within 6 months\n   * Major surgery\u002Fsevere trauma within 30 days pre-PCI\n   * Planned non-deferrable major surgery during dual antiplatelet therapy\n\n   Minor Criteria:\n   * Age ≥75 years\n   * Moderate chronic kidney disease (eGFR:30\\~59 ml\u002Fmin)\n   * Mild anemia (male: Hb=110\\~129 g\u002FL; female: Hb=110\\~119 g\u002FL)\n   * Spontaneous bleeding requiring hospitalization\u002Ftransfusion within 6-12 months pre-PCI\n   * Chronic NSAID\u002Fsteroid use post-PCI\n   * Ischemic stroke \\>6 months pre-PCI\n6. Capable of understanding trial objectives and providing informed consent\n\nAngiographic Inclusion Criteria:\n\n1. Target lesion must be primary native coronary artery lesion\n2. Target lesion with ≥70% diameter stenosis (visual estimate), or 50-70% diameter stenosis (visual estimate) with ischemic evidence\n3. ≥1 non-target lesion requiring intervention\n4. Non-target lesions eligible for elective treatment within 1 month\n\nExclusion Criteria:\n\nGeneral Exclusion Criteria:\n\n1. Presence of ≥1 evidence of heart failure including:\n\n   * NYHA Class III or higher, or\n   * Killip classification ≥ Grade 2, or\n   * Left ventricular ejection fraction (LVEF) ≤30% within 30 days pre-procedure (by echocardiography or intraoperative ventriculography)\n2. Cardiogenic shock patients\n3. Known allergies to: Aspirin \u002F clopidogrel \u002F ticagrelor \u002F heparin, Contrast agents\u002Fdrugs used in drug-eluting stents or contraindications to aspirin\u002F clopidogrel \u002F ticagrelor\n4. Life expectancy \\\u003C12 months or factors potentially compromising clinical follow-up\n5. Participation in other drug\u002Fmedical device trials prior to enrollment without reaching primary endpoint timelines\n6. History of substance abuse (alcohol\u002Fcocaine\u002Fheroin, etc.)\n7. Severe arrhythmias (e.g., high-risk ventricular premature contractions\u002F ventricular tachycardia)\n8. Other medical conditions deemed unsuitable by investigators\n\nAngiographic Exclusion Criteria:\n\n1. Left main coronary artery disease\n2. Bypass graft lesions\n3. Evidence of extensive thrombus in target vessel",{"count":189,"type":19},60,[107],"BioFreedom™ is the world's first polymer-free drug-coated stent (DCS), utilizing a proprietary microstructured surface technology. Its abluminal microporous surface directly carries BA9™ (a sirolimus derivative) with high lipophilicity. This design mitigates inflammatory responses while promoting early vascular healing and reducing thrombotic risk. Extensive clinical evidence has validated BioFreedom™'s superior performance in high-bleeding-risk (HBR) populations. However, comprehensive assessments of neointimal coverage and quantitative neointimal transformation post-implantation remain insufficient. With advancements in ultra-high-resolution optical coherence tomography (OCT), detailed evaluation of coronary stent healing has become feasible. This study will employ OCT to comparatively assess vascular healing patterns-including neointimal transformation and strut coverage-in ACS patients with HBR receiving either the commercially available BioFreedom™ DCS or Xience drug-eluting stent system. The findings will provide multidimensional insights into the devices' post-implantation efficacy and safety profiles.",[25,193],"Acute Coronary Syndrome","2026-03-31",{"date":196,"type":31},"2026-04-06",{"date":198,"type":31},"2025-12-10",{"date":200,"type":19},"2027-03-31",{"name":95,"class":96},{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":75,"phases":212,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":4},"100631936","timing-of-endoscopy-in-coronary-heart-disease-patients-taking-antiplatelet-drugs-with-acute-non-variceal-upper-gastrointestinal-bleeding-100631936","NCT07507162","Timing of Endoscopy in Coronary Heart Disease Patients Taking Antiplatelet Drugs With Acute Non-variceal Upper Gastrointestinal Bleeding","A Prospective Randomized Controlled Study on the Timing of Endoscopy in Coronary Heart Disease Patients Taking Antiplatelet Drugs With Acute Non-variceal Upper Gastrointestinal Bleeding","PACT-UGIB","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients with coronary heart disease receiving antiplatelet therapy\n* Patients who can tolerate general anesthesia and endoscopy after anesthesia evaluation\n* Voluntary participation in the clinical trial and signed informed consent\n\nExclusion Criteria:\n\n* Patients with unstable vital signs despite fluid resuscitation, blood transfusion, and other supportive treatments\n* Presence of contraindications to endoscopy\n* Patients with confirmed or suspected variceal upper gastrointestinal bleeding\n* Gastrointestinal bleeding suspected to originate from the middle or lower gastrointestinal tract",{"count":211,"type":19},212,[107],"This is a prospective randomized controlled trial (RCT) evaluating the optimal timing of endoscopy in patients with coronary heart disease who are taking antiplatelet drugs and present with acute non-variceal upper gastrointestinal bleeding.\n\nEligible patients will be randomly assigned to one of two groups: an urgent endoscopy group (undergoing endoscopy within 12 hours of hospital admission) or an early endoscopy group (undergoing endoscopy between 12 and 24 hours after admission). All patients will receive standard medical treatment for upper gastrointestinal bleeding and antiplatelet management in accordance with current clinical guidelines.\n\nThe primary outcome of this study is the incidence of major adverse cardiovascular events (MACE) within 30 days between the two groups. Secondary outcomes include further bleeding events, all-cause mortality, length of hospital stay, and the need for blood transfusion during the follow-up period.\n\nThis research aims to generate evidence-based clinical guidance on the safest and most effective endoscopy timing for this high-risk patient population.",[215,25],"Acute Non-variceal Upper Gastrointestinal Hemorrhage","2026-03-30",{"date":218,"type":31},"2026-04-02",{"date":220,"type":19},"2026-04-01",{"date":222,"type":19},"2030-12-31",{"name":65,"class":38},{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":16,"minAge":231,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":75,"phases":235,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":39},"100630894","phase-1-a-study-on-yiyang-huoluo-decoction-in-the-treatment-of-coronary-heart-disease-100630894","NCT07493603","A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease","Clinical and Basic Research on the Treatment of Senile Atherosclerosis and Coronary Heart Disease With Yiyang Huoluo Decoction","Inclusion Criteria:\n\nAll of the following conditions must be met simultaneously for enrollment:\n\n* ① Meet the diagnostic criteria for stable angina pectoris;\n* ② Classified as Grade I to III according to the Canadian Cardiovascular Society (CCS) Angina Grading Scale;\n* ③ Meet the diagnostic criteria for chest discomfort syndrome due to yang qi deficiency and decline (a traditional Chinese medicine pattern differentiation);\n* ④ Aged between 50 and 75 years old;\n* ⑤ Received drug-eluting stent implantation due to severe vascular stenosis (single artery ≥75%， or LM ≥50%) detected by coronary angiography;\n* ⑥ Able to actively comply with medical instructions and voluntarily sign the written informed consent form.\n\nExclusion Criteria:\n\nParticipants will be excluded if they meet any of the following conditions:\n\n* ① Diagnosed with acute coronary syndrome (including acute ST-segment elevation myocardial infarction, acute non-ST-segment elevation myocardial infarction, and unstable angina pectoris) after relevant examinations;\n* ② Suffer from chest pain caused by non-cardiac diseases other than stable angina pectoris; or have complicated severe hypertension (systolic blood pressure ≥ 180mmHg and\u002For diastolic blood pressure ≥ 110mmHg), severe cardiopulmonary insufficiency, or malignant tumor;\n* ③ Have severe endocrine, hematological or rheumatic immune system diseases, severe hepatic and renal dysfunction, active gastrointestinal bleeding, or mental illness;\n* ④ Have an allergic constitution or a history of allergic reactions to traditional Chinese medicine;\n* ⑤ Have incomplete major baseline data that may affect the trial results, or have participated in other clinical trials recently.","50 Years","75 Years",{"count":234,"type":19},30,[236,237],"PHASE1","PHASE2","The goal of this clinical trial is to learn if Yiyang Huoluo Decoction (a custom Chinese herbal medicine) works safely and effectively to treat coronary heart disease with atherosclerosis in older adults. It also aims to find out how this herbal treatment may affect blood vessel health and repair at a cellular level.\n\nThe main questions it aims to answer are:\n\n* Does adding Yiyang Huoluo Decoction to standard Western medical care improve symptoms and heart-related health in older adults with coronary heart disease and atherosclerosis?\n* Is Yiyang Huoluo Decoction safe for older adults to take alongside their regular heart medications?\n* How does this herbal treatment affect the damaged blood vessels in study participants?\n\nResearchers will compare two groups of participants to see if the combined treatment works better than standard care alone.\n\nWho can take part: Older adults diagnosed with coronary heart disease and atherosclerosis who meet the study's health and eligibility rules.\n\nWhat participants will do:\n\n* Be split randomly into two groups of 15 people each: one group gets standard Western heart medicine only, and the other gets standard Western heart medicine plus Yiyang Huoluo Decoction (herbal granules)\n* Complete the 12-week decoction treatment plan as directed by the research team\n* Attend scheduled study visits for health checks, blood tests, heart and blood vessel scans (such as carotid ultrasound and coronary CTA), and symptom reviews\n* Provide two small blood samples for research testing (samples will be destroyed after study testing is finished)\n* Report any side effects, discomfort, or changes in health to the research team right away\n\nAll personal health information collected for this study will be kept private and confidential. Participation is completely voluntary, and participants may quit the study at any time for any reason without losing access to regular medical care.",[25,24,240],"Atheroscleroses","2026-03-23",{"date":243,"type":31},"2026-03-25",{"date":245,"type":31},"2026-01-16",{"date":247,"type":19},"2028-06-30",{"name":249,"class":38},"Xia Liang",{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":258,"minAge":47,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":75,"phases":261,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":39},"100554059","exercise-training-in-women-with-heart-disease-2-100554059","NCT06494163","Exercise Training in Women With Heart Disease 2","Exercise Training in Women With Heart Disease: A Randomized Controlled Trial","EXCEED2","Inclusion Criteria:\n\n1. Women (i.e., female sex assigned at birth) with CHD (e.g., coronary artery bypass grafting surgery \\[CABG\\], percutaneous coronary intervention \\[PCI\\], acute myocardial infarction \\[MI\\], MI with no obstructive coronary artery disease \\[MINOCA\\], or ischemia with no obstructive coronary artery disease \\[INOCA\\] at least 4 weeks post procedure or event; based on clinical evidence this is a safe period of time to exercise);\n2. Patient is able to perform a symptom limited CPET (this is the primary outcome and needed to determine peak HR for the exercise training prescription); and\n3. Patient is able to read and understand English or French.\n\nExclusion Criteria:\n\n1. Patient is currently participating in routine exercise training (\\>2x\u002Fweek, routine exercise training is defined as a planned, structured, and repetitive exercise that is performed in order to maintain or improve physical fitness.) (this may reduce the impact of HIIT or MICT on outcomes);\n2. Patient has: NYHA class III-IV heart failure symptoms; unstable angina; or established diagnosis of chronic obstructive pulmonary disease, severe mitral or aortic stenosis, or hypertrophic obstructive cardiomyopathy (this may interfere with the ability to engage in MICT or HIIT);\n3. Patient has uncontrolled arrhythmia (this may impact the HR-based exercise training prescription and monitoring);\n4. Patient is unable to provide written informed consent; or\n5. Patient is unwilling or unable to return for follow-up visits at 12 and 26 weeks.\n6. Patient is unwilling to be randomized to HIIT or MICT.","FEMALE",{"count":260,"type":19},172,[107],"This study will compare the effects of two different types of training on exercise capacity in women with coronary heart disease (CHD). Participants will be randomized into either the virtual high-intensity interval training (HIIT) or the virtual moderate-to-vigorous intensity continuous training (MICT). After randomization, patients will exercise twice a week, for 12 weeks. The sessions will be conducted virtually. Patients will undergo a maximal exercise test, cardiometabolic indicators (height (cm), body mass (kg), body composition (%), waist circumference (cm) and, resting blood pressure) and complete questionnaires about quality of life, mental health, self-determined motivation, self-efficacy and enjoyment.",[264,25],"Cardiovascular Diseases","2026-03-09",{"date":267,"type":31},"2026-03-11",{"date":269,"type":31},"2025-01-27",{"date":271,"type":19},"2029-03-30",{"name":273,"class":38},"Ottawa Heart Institute Research Corporation",{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":284,"conditions":285,"keywords":286,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":39},"100627687","glycocalyx-and-oxidative-stress-in-endothelial-function-part-2-100627687","NCT07451873","Glycocalyx and Oxidative Stress in Endothelial Function (Part 2)","The Role of Glycocalyx and Oxidative Stress in Endothelial Function (Part 2)","GlikoOxEND","Inclusion Criteria:\n\n* adult patients of both sexes over 18 years of age\n* Caucasian\n* undergoing elective coronary artery bypass grafting (CABG)\n* provided written informed consent\n\nExclusion Criteria:\n\n* emergency surgery\n* sepsis or severe systemic inflammation before surgery\n* severe renal or hepatic insufficiency\n* immunosuppression\n* serious comorbidities (e.g., active cancer)\n* therapies that could affect oxidative stress (e.g., high doses of corticosteroids)",{"count":283,"type":19},35,"The primary research objective of the project is to determine the role of eGC in microvascular reactivity in patients with coronary heart disease (CHD) before and after bypass grafting (cross-sectional study 2).The main objective of the project is to increase the excellence and interdisciplinarity of scientific work at MEFOS by connecting researchers from different scientific fields, improving conditions and resources for scientific work, and increasing international cooperation, in line with strategic objective 1: raising scientific excellence. The results of the project could provide pathophysiological insight into the development and maintenance of endothelial dysfunction in CVD, as well as identify new biomarkers for CVD.",[25],[287,288,289,290,24,291],"Glycocalyx","Inflammation","Oxidative stress","Endothelium","Myocardial Revascularization","2026-03-05",{"date":265,"type":31},{"date":295,"type":31},"2025-10-01",{"date":297,"type":19},"2029-09-30",{"name":299,"class":38},"Josip Juraj Strossmayer University of Osijek",{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":304,"acronym":305,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":232,"enrollmentInfo":307,"targetDuration":4,"studyType":75,"phases":309,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":321},"100618505","digital-remote-management-for-care-and-continuous-optimization-versus-usual-care-in-patients-with-coronary-heart-disease-digicare-chd-100618505","NCT07332494","Digital Remote Management for Care and Continuous Optimization Versus Usual Care in Patients With Coronary Heart Disease (DigiCare-CHD)","DigiCare-CHD","Inclusion Criteria:\n\n1. Age 18-75 years\n2. Diagnosis of Acute Coronary Syndrome (ACS) or Chronic Coronary Syndrome (CCS)\n3. Status post-successful percutaneous coronary intervention (PCI).\n4. Possession of a smartphone and ability to operate the application (independently or with caregiver assistance).\n5. Provision of written informed consent.\n\nExclusion Criteria:\n\n1. Heart Failure: NYHA Class III-IV or LVEF \\\u003C 40%.\n2. Severe hepatic dysfunction (ALT\u002FAST ≥3xULN or Total Bilirubin \\>1.5 mg\u002Fdl)\n3. Severe renal dysfunction (eGFR \\\u003C 30 ml\u002Fmin\u002F1.73m² or requiring dialysis)\n4. Uncontrolled hypothyroidism (TSH \\>1.5xULN or \\>10 mIU\u002FL, or unstable dosage within 6 weeks)\n5. Life expectancy \\\u003C 1 year due to non-cardiovascular comorbidities\n6. Severe sensory (hearing\u002Fvision) or cognitive impairment precluding device use\n7. Conditions affecting adherence (e.g., substance use disorder, history of alcohol abuse)",{"count":308,"type":19},792,[107],"The DigiCare-CHD study is an investigator-initiated, multicenter, open-label, parallel-group randomized controlled trial. It aims to evaluated the efficacy of a smartphone-based digital remote management platform compared to usual care in achieving dual goal attainment of blood pressure and LDL-cholesterol levels in patients with coronary heart disease following percutaneous coronary intervention.",[25,312],"Percutaneous Coronary Intervention","2025-12-31",{"date":315,"type":31},"2026-01-12",{"date":317,"type":19},"2026-01",{"date":319,"type":19},"2027-07",{"name":65,"class":38},4,{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":16,"minAge":136,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":75,"phases":333,"briefSummary":334,"conditions":335,"keywords":337,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":344,"completionDateStruct":346,"leadSponsor":347,"locationsCount":350},"100601432","phase-4-efficacy-and-safety-trials-of-yangxinshi-tablets-in-the-treatment-of-patients-with-coronary-heart-disease-complicated-by-cardiac-dysfunction-100601432","NCT07110415","Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction","A Randomized Controlled Trial of the Efficacy and Safety of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction","HEARTPOWER","Inclusion Criteria:\n\n1. For inpatients diagnosed with coronary heart disease (including acute coronary syndrome and chronic coronary syndrome), it is up to the doctor to decide whether to undergo revascularization and what kind of revascularization to use.\n2. Patients aged between 40 and 80 years (inclusive), regardless of sex;\n3. Patients with NYHA cardiac function classes II-IV;\n4. Patients with NT-proBNP \\> 125 pg\u002FmL (or BNP\\>35 pg\u002FmL);\n5. The syndrome differentiation in traditional Chinese medicine conforms to chest obstruction (qi deficiency and blood stasis syndrome)\n6. Patients who voluntarily participated and signed an informed consent form.\n\nExclusion Criteria:\n\n1. Patients with STEMI within 3 days;\n2. Patients at extremely high risk of NSTEMI (hemodynamic instability, cardiogenic shock, new-onset heart failure or aggravated heart failure, severe ventricular arrhythmia)\n3. Patients with acute myocardial infarction complicated with cardiogenic shock, mechanical complications, respiratory failure and other multiple organ failure;\n4. Patients with severe liver dysfunction (transaminase levels more than three times the upper limit of normal), renal insufficiency (eGFR \\\u003C 30mL\u002Fmin\u002F1.73m2), acute infectious diseases, and mental disorders;以上翻译结果来自有道神经网络翻译（YNMT）· 通用场景\n5. Patients with drug-resistant hypertension (systolic blood pressure ≥180 mmHg and\u002For diastolic blood pressure ≥110 mmHg);\n6. Pregnant or lactating women, or those planning pregnancy during the study period;\n7. Patients who cannot tolerate 3 months of dual antiplatelet therapy;\n8. Patients with allergic reactions or abnormal drug reactions to the study drug or any of its excipients;\n9. Patients who have regularly taken Yangxinshi tablets and similar traditional Chinese medicine, Chinese patent medicine or traditional Chinese medicine decoction with the same curative effectin the past month;\n10. Patients who have participated in other clinical drug trials within the last three months;\n11. Patients with malignant tumors and other pathological conditions with an expected survival of less than 3 years;\n12. Patients whom the investigator deems unsuitable for participating in the clinical trial.","80 Years",{"count":332,"type":19},2708,[77],"A randomized controlled trial was conducted to evaluate the efficacy and safety of Yangxinshi tablets in improving the condition of patients with coronary heart disease complicated by cardiac dysfunction.",[25,336],"Cardiac Dysfunction",[338,339,340],"Yangxinshi","Coronary heart disease","Cardiac dysfunction","2025-11-20",{"date":343,"type":31},"2025-11-25",{"date":345,"type":31},"2025-11-06",{"date":222,"type":19},{"name":348,"class":349},"SPH Qingdao Growful Pharmacetical Co.,Ltd","INDUSTRY",96,{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":75,"phases":359,"briefSummary":360,"conditions":361,"keywords":362,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":4},"100606234","nutrition-education-by-nurses-in-patients-after-coronary-artery-bypass-grafting-effect-on-patients-dietary-pattern-adherence-and-clinical-outcomes-100606234","NCT07172906","\"Nutrition Education by Nurses in Patients After Coronary Artery Bypass Grafting: Effect on Patients' Dietary Pattern, Adherence and Clinical Outcomes\"","Inclusion Criteria:\n\n* Age over 18 years\n* Patients who underwent CABG and were discharged from the hospital in the previous 10 days\n* Knowledge of reading and writing in Greek by the patients\n* Provision of written informed consent by the patients for their participation in the study\n\nExclusion Criteria:\n\n* History of psychiatric illness, recent history of alcohol and\u002For drug abuse, dementia or Alzheimer's disease\n* Patients with comorbidities (diabetes mellitus, chronic renal failure, idiopathic inflammatory bowel disease, other gastrointestinal disorders, food allergies, etc.) that would justify the adoption of a special dietary pattern that is not identical to the proposed dietary pattern\n* Patients with a preference for strict vegetarianism (vegan) and\u002For cultural-religious beliefs that do not allow the adoption of the proposed dietary pattern",{"count":358,"type":19},160,[107],"The purpose of this study is the investigation of the effect of nurse-led nutritional education of post-CABG patients on their dietary pattern, on their adherence to it, but also on their quality of life and well-being.",[25],[363,364,365,366],"Coronary Artery Bypass Grafting","Nutritional Education from nurses","Weight measurement","adherence to the Mediterranean diet","2025-09-08",{"date":369,"type":31},"2025-09-15",{"date":371,"type":19},"2025-10",{"date":373,"type":19},"2027-10",{"name":375,"class":38},"Hellenic Mediterranean University",{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":4,"eligibilityCriteria":382,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":75,"phases":385,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":395},"100548755","phase-4-effect-of-xuesaitong-soft-capsules-on-major-risk-factors-in-patients-with-coronary-heart-disease-100548755","NCT06425120","Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease","Effect of Xuesaitong Soft Capsules on Major Risk Factors in Patients With Coronary Heart Disease: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n1. Age ≥18 years old\n2. Chronic coronary artery disease: meet any of the following conditions, and the condition is stable for at least 3 months:\n\n   1. History of myocardial infarction\n   2. Have received coronary interventional therapy\n   3. There are symptoms of myocardial ischemia (such as chest pain) and objective evidence (stress electrocardiogram or stress myocardial perfusion imaging indicated myocardial ischemia or coronary artery stenosis ≥50% )\n3. High-sensitivity C-reactive protein ≥2mg\u002FL\n4. Currently taking moderate or above intensity statins lipid-lowering drugs\n5. Currently taking antiplatelet drugs\n6. Sign informed consent\n\nExclusion Criteria:\n\n* Patients fulfilling any of the following criteria are not eligible for inclusion in this trial:\n\n  1. Acute coronary syndrome occurred or received percutaneous coronary intervention therapy within the past 3 months\n  2. Previously received coronary artery bypass grafting\n  3. Stroke occurred within the previous 3 months\n  4. Symptomatic heart failure (HF) in the past, or documented left ventricular ejection fraction \\\u003C 35%\n  5. Revascularization or surgical procedures are planned within the next 3 months\n  6. Progressive neuromuscular disease, or creatine kinase (CK) levels \\> 3 times the normal upper limit (ULN)\n  7. Lupus, inflammatory bowel disease, severe arthritis and other inflammatory diseases\n  8. Immunosuppressants such as cyclosporine, tacrolimus, azathioprine, or systemic steroids are currently being taken or planned during the study\n  9. History of hereditary dyslipidemia such as familial hypercholesterolemia\n  10. There has been a change in lipid regulation treatment within the past 1 month, or there is a current adjustment plan\n  11. History of symptomatic non-traumatic cerebral hemorrhage at any time in the past\n  12. History of gastrointestinal bleeding or major surgery within the past 6 months\n  13. Use of Xuesaitong soft capsules or preparations containing the main ingredients of Xuesaitong in the past 1 month\n  14. There were clear adverse reactions to the main components of Xuesaitong in the past\n  15. Active liver disease, or alanine aminotransferase (ALT) levels \\> 3 times the upper limit of normal (ULN)\n  16. Chronic kidney disease, or estimated glomerular filtration rate (eGFR) \\\u003C60ml\u002F (min×1.73m2)\n  17. Pregnancy or planned pregnancy, or breastfeeding\n  18. Malignant tumors, or other serious diseases with an estimated survival of less than 1 year\n  19. Mental disorders or communication disorders, cognitive impairment, or other serious medical conditions that may affect study participation\n  20. Have participated in or are participating in other clinical trials within the last 1 month\n  21. Poor adherence to follow-up or medication is known",{"count":384,"type":19},240,[77],"This trials aims to assess, in 240 eligible patients with coronary heart disease, the effects on level of high-sensitivity C-reactive protein (hsCRP) changes from baseline to 12 weeks of Xuesaitong Soft Capsules.",[25],"2025-08-30",{"date":367,"type":31},{"date":391,"type":31},"2024-06-01",{"date":393,"type":19},"2026-12-31",{"name":95,"class":96},2,{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":232,"enrollmentInfo":403,"targetDuration":4,"studyType":75,"phases":405,"briefSummary":406,"conditions":407,"keywords":409,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":39},"100602086","phase-2-study-of-sivelestat-sodium-in-opcabg-100602086","NCT07118930","Study of Sivelestat Sodium in OPCABG","Prospective Double-Blind Controlled Study of Sivelestat Sodium in the Perioperative Management of Off-Pump Coronary Artery Bypass Grafting","Inclusion Criteria:\n\n* Undergoing elective OPCABG (≥2 bridged vessels). LVEF≥35%, no severe liver or kidney function abnormalities (ALT\u002FAST≤3 times the upper limit, eGFR≥60 mL\u002Fmin). Sign the informed consent form.\n\nExclusion Criteria:\n\n* Emergency operation, combined valve surgery or aortic surgery. Usage of immunosuppressants or potent anti-inflammatory drugs within 30 days before the operation.\n* Active infections, autoimmune diseases, and allergy history.\n* Preoperative liver and kidney dysfunction\n* Severe cardiopulmonary insufficiency before the operation.",{"count":404,"type":19},62,[237],"The goal of this clinical trial is to learn if drug Sivelestat Sodium works to improve the prognosis of off-pump coronary artery bypass grafting (OPCABG) in adults. It will also learn about the safety of drug Sivelestat Sodium. The main questions it aims to answer are:\n\n* Does drug Sivelestat Sodium have a protective effect on myocardial injury after OPCABG?\n* Does Sivelestat Sodium exert a protective effect on myocardial inflammatory stress after OPCABG? Researchers will compare drug Sivelestat Sodium to a placebo (a look-alike substance that contains no drug) to see if drug Sivelestat Sodium works to protect myocardium following OPCABG.\n\nParticipants will:\n\n* Accept drug Sivelestat Sodium injection or a placebo 2 h after OPCABG for 72 h.\n* Undergo a series of blood tests and echocardiography examinations after the OPCABG.",[25,24,408],"Coronary Arterial Disease (CAD)",[410,411,412,413,414],"coronary heart disease","coronary artery bypass grafting","Sivelestat Sodium","prognosis","myocardial injury","2025-08-11",{"date":417,"type":31},"2025-08-12",{"date":419,"type":31},"2025-08-01",{"date":421,"type":19},"2027-07-31",{"name":423,"class":38},"Affiliated Hospital of Nantong University",{"id":425,"slug":426,"hasResults":12,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":430,"eligibilityCriteria":431,"healthyVolunteers":135,"sex":16,"minAge":136,"maxAge":137,"enrollmentInfo":432,"targetDuration":4,"studyType":75,"phases":434,"briefSummary":435,"conditions":436,"keywords":437,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":449},"100586124","feasibility-of-innovative-approaches-for-personalized-cardiovascular-prevention-100586124","NCT06911294","Feasibility of Innovative Approaches for Personalized Cardiovascular Prevention","Feasibility of InnovaTive Approaches for Personalized Cardiovascular PREVention: Randomized Controlled Pilot Trial and Multidisciplinary Evaluation for National Health Service Implementation","FITPREV","Inclusion Criteria:\n\n* Age 40-69 years;\n* 10 year cardiovascular risk score SCORE2 between 2.5% and 10%.\n* Diagnosis of metabolic syndrome according to the American Heart Association criteria , defined as the presence of three or more of the following:\n\n  * Central or abdominal obesity, measured by waist circumference (greater than 40 inches - 102 cm in men and 35 inches - 89 cm in women).\n  * Elevated triglycerides: levels equal to or greater than 150 mg\u002FdL or use of medication for hypertriglyceridemia.\n  * Low HDL cholesterol levels (less than 40 mg\u002FdL in men and less than 50 mg\u002FdL in women) or use of cholesterol-lowering medication.\n  * Elevated blood pressure: systolic ≥130 mmHg or diastolic ≥85 mmHg, or use of antihypertensive medication.\n  * Elevated fasting blood glucose: ≥100 mg\u002FdL or use of glucose-lowering medication.\n\nExclusion Criteria:\n\n* Diabetes:\n* Familial hypercholesterolemia;\n* Previous cardiovascular events.",{"count":433,"type":19},120,[107],"The goal of the FITPREV (Feasibility of InnovaTive approaches for personalized cardiovascular PREVention: randomized controlled pilot trial and multidisciplinary evaluation for National Health Service implementation) clinical trial is to study the feasibility of innovative approaches( Polygenic Risk Score and health smartwatch) for personalized primary preventive interventions in cardiovascular diseases (CVD). The main questions it aims to answer are:\n\n* Feasibility of a greater study.\n* Feasibility of the interventions in a realistic setting, such as the medical office of a General Practitioner.\n\nParticipants will be randomized in one of the four parallel arms:\n\n* standard of care;\n* genetic testing for cardiovascular genetic risk (through the cardiovascular Polygenic Risk Score or PRS);\n* digital intervention with a wearable device and its app;\n* digital intervention and genetic testing\n\nThe primary outcomes that are going to be evaluated are patient's and General Practitioners' overall judgment of the study and its feasibility.\n\nSecondarily the efficacy of returning Polygenic Risk Score (PRS) results will be assessed. This will happen on two endpoints: i) change in lifestyle pattern; ii) CVD risk profile modification. The postulated hypothesis is that the achievement of these endpoints is more likely in presence of at least one of the aforementioned interventions than among subjects who receive only traditional risk assessment at baseline.",[25],[438,439],"coronary artery disease","Polygenic Risk Score","2025-08-04",{"date":442,"type":31},"2025-08-05",{"date":444,"type":31},"2025-02-10",{"date":446,"type":19},"2026-09-10",{"name":448,"class":38},"Catholic University of the Sacred Heart",7,{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":12,"sex":16,"minAge":458,"maxAge":330,"enrollmentInfo":459,"targetDuration":4,"studyType":75,"phases":461,"briefSummary":463,"conditions":464,"keywords":465,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":39},"100541218","early-phase-1-thiamine-intervention-and-coronary-artery-bypass-grafting-100541218","NCT06326996","Thiamine Intervention and Coronary Artery Bypass Grafting","Thiamine Intervention and Cognition in Older Adults Undergoing Coronary Artery Bypass Grafting - A Randomized Clinical Trial.","B1&CABG","Inclusion Criteria:\n\n* Patients with Coronary Heart Disease (CHD) scheduled for Bypass Grafting (CABG)\n* Thiamine deficiency before CABG\n* European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) \\>1.5%\n* Off-pump surgery\n\nExclusion Criteria:\n\n* Dementia at baseline \\[Montreal Cognitive Assessment (MoCA) \\\u003C21 within 5 days before CABG\\]\n* Current in-take of thiamine\n* Known thiamine allergy\n* Uncontrolled blood glucose levels\n* Unable to give consent due to illness\n* History of hyperlactatemia\n* Recent (within several years and\u002For up to the judgment of the PI\u002Fco-PIs) cerebral incidents (seizure or head trauma resulting in loss of consciousness and\u002For concussion)\n* Stroke\n* Diagnosed psychiatric diseases (clinical depression, schizophrenia, manic-depression)\n* Patients with history of alcohol or substance abuse\n* Acute or chronic infections (tuberculosis, hepatitis, or encephalopathy)\n* Diagnosed neuro-degenerative diseases (Alzheimer's or Parkinson's disease)\n* Chronic immunodeficiency (including HIV)\n* Congenital brain deficits will also be excluded","60 Years",{"count":460,"type":19},52,[462],"EARLY_PHASE1","The purpose of this study is to gain a better understanding of the association between brain changes and cognitive deficits in coronary heart disease (CHD) patients undergoing coronary artery bypass grafting (CABG) and whether a low-cost thiamine intervention can be used to reduce post-CABG cognitive issues in CHD subjects.",[25,363],[466],"thiamine intervention","2025-07-30",{"date":419,"type":31},{"date":470,"type":31},"2024-10-10",{"date":472,"type":19},"2026-09-30",{"name":474,"class":38},"University of California, Los Angeles",{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":481,"enrollmentInfo":482,"targetDuration":4,"studyType":75,"phases":484,"briefSummary":485,"conditions":486,"keywords":494,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":39},"100519889","lifestyle-medicine-establishing-clinical-approaches-to-chronic-disease-for-rural-patients-100519889","NCT06049420","Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients","Inclusion Criteria:\n\n* Program admittance will be restricted to patients with 2+ diagnosed diseases that have sufficient evidence for the efficacy of exercise therapy (obesity, hyperlipidemia, metabolic syndrome, polycystic ovarian syndrome, type II diabetes, hypertension, coronary heart disease, heart failure, depression, anxiety)\n* physician referral required\n\nExclusion Criteria:\n\n* no chronic disease diagnosis, lack of physician referral, unwillingness to participate.","64 Years",{"count":483,"type":19},95,[107],"Developed nations worldwide are currently enduring a health crisis, as chronic diseases continue to decrease quality of life and promote additional disease states or even death for much of the population. Rural populations are at a particular disadvantage, as they lack access to health clubs, wellness programs and similar resources that are more available in urban areas. Although pharmaceutical therapies have continued to show therapeutic advancements, the rates of disease onset and death from chronic disease has not seen similar improvements, and in fact continue to worsen. Excitingly, significant evidence has been published demonstrating an affordable, effective treatment to directly treat and prevent these chronic diseases, but few have demonstrated successful implementation of this therapy, which is improved lifestyle. Specifically, physical activity and healthy body composition are powerful therapeutics that have been demonstrated to effectively combat and prevent chronic diseases. Additionally, improving these lifestyle factors are often more effective than pharmaceutical interventions without the wide range of side effects. Unfortunately, barriers exist on multiple tiers in the practice of family medicine that demote the implementation of lifestyle medicine. To better serve patients at risk of, or suffering from chronic disease, the investigators are seeking to establish a lifestyle medicine prescription program for rural West Virginia. This program will provide patient education on the benefits of physical activity, body composition, and help patients identify strategies to implement healthy lifestyle choices that can be sustainable for the long-term. Patients will be advised on local opportunities to increase physical activity (yoga studio, martial arts, fitness facilities, aquatic center, etc.) and provided access to the facilities they are most likely to adhere to regularly. They will also be provided training on exercise techniques, equipment, and facilities to increase familiarity and comfort in these settings.",[85,487,488,489,25,490,491,492,493],"Hyperlipidemias","Polycystic Ovary Syndrome","Hypertension","Heart Failure","Depression, Anxiety","Type II Diabetes","Metabolic Syndrome",[495,496,497],"lifestyle","chronic disease","physical activity","2025-07-21",{"date":500,"type":31},"2025-07-25",{"date":502,"type":31},"2025-02-01",{"date":504,"type":19},"2027-09-01",{"name":506,"class":38},"West Virginia School of Osteopathic Medicine",{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":512,"acronym":4,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":16,"minAge":136,"maxAge":232,"enrollmentInfo":514,"targetDuration":4,"studyType":75,"phases":516,"briefSummary":517,"conditions":518,"keywords":519,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":39},"100509818","project-3-achieve--chd-100509818","NCT05918380","Project 3: ACHIEVE- CHD","ACHIEVE GREATER: Addressing Cardiometabolic Health In Populations Through Early Prevention in the Great Lakes Region","Inclusion Criteria:\n\n1. 40 to 75 years of age\n2. Self-identified as Black or African American\n3. Residence in the Cleveland Metro Area\n4. Must have at least two of the following risk factors identified at a UH health fair screenings, with one risk factor being with SBP, A1c, or LDL:\n\n   1. BMI≥30 mg\u002FdL\n   2. History of smoking\n   3. Elevated blood pressure defined as SBP\\>140 or DBP\\>80 mmHg\n   4. HbA1c≥5.7%\n   5. LDL≥130\n5. Able to complete a coronary artery calcium score test (CAC)\n6. Willing and able to consent\n7. Willing to have a UH provider and UH care\n8. Currently insured for standard of care procedures\n\nExclusion Criteria:\n\n1. Established documented cardiovascular disease (coronary artery disease, peripheral artery disease, myocardial infarction, stroke).\n2. Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg\n3. Lung disease requiring supplemental oxygen therapy\n4. Individuals receiving treatment for cancer related disease\n5. Pregnant or nursing mothers",{"count":515,"type":19},500,[107],"This project is part of the ACHIEVE GREATER (Addressing Cardiometabolic Health In Populations Through Early Prevention in the Great Lakes Region) Center (IRB 100221MP2A), the purpose of which is to reduce cardiometabolic health disparities and downstream Black-White lifespan inequality in two cities: Detroit, Michigan, and Cleveland, Ohio. The ACHIEVE GREATER Center will involve three separate but related projects that aim to mitigate health disparities in risk factor control for three chronic conditions, hypertension (HTN, Project 1), heart failure (HF, Project 2) and coronary heart disease (CHD, Project 3), which drive downstream lifespan inequality. All three projects will involve the use of Community Health Workers (CHWs) to deliver an evidence-based practice intervention program called PAL2. All three projects will also utilize the PAL2 Implementation Intervention (PAL2-II), which is a set of structured training and evaluation strategies designed to optimize CHW competence and adherence (i.e., fidelity) to the PAL2 intervention program. The present study is Project 3 of the ACHIEVE GREATER Center.",[25],[520,521,522,25],"Health Disparities","African American","Prevention","2025-07-09",{"date":525,"type":31},"2025-07-14",{"date":527,"type":31},"2022-08-15",{"date":529,"type":19},"2027-01-01",{"name":531,"class":38},"University Hospitals Cleveland Medical Center",{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":539,"enrollmentInfo":540,"targetDuration":4,"studyType":75,"phases":542,"briefSummary":543,"conditions":544,"keywords":545,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":39},"100371715","safety-and-efficacy-of-dcb-therapy-for-isr-under-the-guidance-of-qfr-unique-dcb-ii-study--100371715","NCT04119986","Safety and Efficacy of DCB Therapy for ISR Under the Guidance of QFR (UNIQUE-DCB-II Study )","Safety and Efficacy of Drug Coated Balloon Therapy for Coronary In-stent Restenosis in Patients With Coronary Heart Disease Under the Guidance of QFR (UNIQUE-DCB-II Study)","Inclusion Criteria:\n\n● Meet the diagnostic criteria for patients with coronary in-stent restenosis and QFR\\\u003C0.8 of target lesion in the coronary stent\n\nExclusion Criteria:\n\n* QFR less than 0.8, dissection above type B and thrombosis formation after pre-dilation of ISR\n* Severe congestive heart failure \\[LVEF \\\u003C30% or NYHA( New York Heart Association) III\u002FIV)\\]\n* Severe valvular heart disease\n* Life expectancy no more than 1 year or factors causing difficulties in clinical follow up\n* Intolerance to aspirin and\u002For clopidogrel\n* Known intolerance or allergy to heparin, contrast agents, paclitaxel, iopromide, rapamycin, polylactic acid-glycolic acid copolymer, Co-Cr alloy or platinum-chromium alloy\n* Leukopenia or thrombopenia\n* A history of peptic ulcer or GI bleeding in the previously\n* Stroke within 6 months prior to the operation\n* A history of severe hepatic or renal failure","100 Years",{"count":541,"type":19},220,[107],"In 1970, the first percutaneous balloon coronary angioplasty opened a new chapter of interventional therapy. However, the incidence of intracoronary restenosis was about 30%. Subsequently, bare metal stents and drug-eluting stents (DES) reduced the incidence of in-stent restenosis (ISR) to 5%-10% and it was still a bottleneck treated by percutaneous coronary intervention (PCI). Currently, ISR is mainly treated by balloon angioplasty, stent implantation and coronary artery bypass grafting.\n\nIn 2014, the guidelines of the European Society of Cardiology recommended that drug balloon therapy (DCB) and new generation DES should be the preferred strategies for ISR treatment. Compared with DES, DCB treatment can avoid the inflammation of intima caused by multi-layer stent strut, and reduce the risk of intimal hyperplasia and thrombosis in stent. However, DCB lacks sustained radial support. Even if the residual stenosis is less than 30% after sufficient pre-dilation, the elastic retraction of the intima still exists. In addition, the antiproliferative effect of paclitaxel is significantly worse than that of sirolimus and its derivatives, and there is a lack of long-term sustained release of anti-proliferative drugs. Compared with DCB, DES can obtain long-term stable radial support and long-term anti-proliferation effect, but stent struts exposed in the vascular lumen are at risk of stent thrombosis. The new generation of DES improves the design of stent platform, improves the polymer coating, and applies new anti-proliferative drugs. It effectively reduces the inflammation of vascular wall, speeds up the process of vascular re-endothelialization, promotes early vascular repair, and significantly reduces the incidence of stent thrombosis. Recent BIOLUXRCT, RESTORE and DARE studies provide more powerful evidence for the treatment of ISR by new generation DES.\n\nQuantitative flow ratio (QFR) is the second generation FFR detectional method based on coronary contrast image. The latest FAVOR II results also confirm that QFR is more sensitive and specific than quantitative coronary analysis (QCA) in the diagnosis of myocardial ischemia caused by coronary artery stenosis. However, there is no report of ISR treated with DCB under the guidance of QFR. The aim of this study was to evaluate the safety and efficacy of DCB in the treatment of in-stent restenosis in patients with coronary heart disease (CHD) under the guidance of QFR compared with DES implantation.",[25],[546,547,548,549],"Quantitative flow ratio","drug coated balloon","Drug eluted stent","In-stent restenosis","2025-05-27",{"date":552,"type":31},"2025-05-31",{"date":554,"type":19},"2026-01-01",{"date":556,"type":19},"2028-12-01",{"name":558,"class":38},"Nanjing First Hospital, Nanjing Medical University",{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":4,"eligibilityCriteria":565,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":566,"enrollmentInfo":567,"targetDuration":4,"studyType":75,"phases":568,"briefSummary":569,"conditions":570,"keywords":571,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":572,"startDateStruct":573,"completionDateStruct":574,"leadSponsor":575,"locationsCount":39},"100370554","safety-and-efficacy-of-dcb-therapy-for-de-novo-lesions-under-the-guidance-of-qfr-in-chd-patients-unique-dcb-i-study--100370554","NCT04104854","Safety and Efficacy of DCB Therapy for de Novo Lesions Under the Guidance of QFR in CHD Patients (UNIQUE-DCB-I Study )","Safety and Efficacy of Drug Coated Balloon Therapy for de Novo Lesions in Patients With Coronary Heart Disease Under the Guidance of QFR (UNIQUE-DCB-I Study )","Inclusion Criteria:\n\n●Meet the diagnostic criteria for stable angina pectoris, unstable angina pectoris and acute myocardial infarction and QFR\\\u003C0.8 of target lesion\n\nExclusion Criteria:\n\n* QFR less than 0.8, dissection above type B and thrombosis formation after pre-dilation of coronary artery lesions\n* Severe congestive heart failure \\[LVEF \\\u003C30% or NYHA( New York Heart Association) III\u002FIV)\\]\n* Severe valvular heart disease\n* Life expectancy no more than 1 year or factors causing difficulties in clinical follow up\n* Intolerance to aspirin and\u002For clopidogrel\n* Known intolerance or allergy to heparin, contrast agents, paclitaxel, iopromide, rapamycin, polylactic acid-glycolic acid copolymer, Co-Cr alloy or platinum-chromium alloy\n* Leukopenia or thrombopenia\n* A history of peptic ulcer or GI bleeding in the previously\n* Stroke within 6 months prior to the operation\n* A history of severe hepatic or renal failure","90 Years",{"count":541,"type":19},[107],"Since Gruntzig successfully performed percutaneous coronary balloon angioplasty in 1977, percutaneous coronary intervention has developed rapidly. From bare metal stents to drug-eluting stents (DES), the symptoms and prognosis of patients with coronary heart disease (CHD) have been greatly improved. Although DES has reduced the probability of in-stent restenosis (ISR) and thrombosis compared with BMS since its clinical application, it can not completely solve this problem. Even if the new generation of DES requires revascularization, the incidence of ISR is still as high as 5%-10%. DES treatment is associated with delayed endothelial healing, late acquired poor stent adherence and new atherosclerosis, which lead to late ISR and thrombosis. In addition, DES is still not ideal for the treatment of small vessel disease, diffuse long lesion and bifurcation lesion. Therefore, drug coated balloon (DCB) has attracted people's attention. Balloon-loaded antiproliferative drugs can fully release the drugs to the vascular wall during balloon dilation, which can inhibit the restenosis process from the beginning of injury, and show good efficacy and safety in some specific lesions. Many clinical studies have shown that DCB has good efficacy and safety in some specific lesions (ISR, small vessel disease, bifurcation disease, in situ lesion). Especially in the treatment of ISR, researchers believe that its efficacy is not inferior to DES, and it has the advantage of non-metal residues.\n\nQuantitative flow ratio (QFR) is the second generation FFR detection method based on angiographic images. The diagnostic accuracy of QFR 0.80 for myocardial ischemic stenosis was 92.7%. Compared with QCA, the positive predictive value and negative predictive value of QFR were also significantly better than those of QCA. The latest FAVOR II results also confirm that QFR is more sensitive and specific in diagnosing myocardial ischemia caused by coronary artery stenosis than QCA, and confirm the feasibility of using QFR online in catheter lab to evaluate the functional significance of coronary artery critical lesions. However, there is no report on the treatment of de novo lesions in patients with coronary heart disease by DCB under the guidance of QFR. The aim of this study was to evaluate the safety and efficacy of drug balloon therapy for de novo lesions in patients with CHD under the guidance of QFR compared with DES implantation.",[25],[546,547,548,114],{"date":552,"type":31},{"date":554,"type":19},{"date":556,"type":19},{"name":558,"class":38},{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":581,"acronym":582,"eligibilityCriteria":583,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":4,"enrollmentInfo":584,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":586,"conditions":587,"keywords":600,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":613},"100358354","the-role-of-concomitant-diseases-in-postoperative-complications-risk-stratification-100358354","NCT03945968","The Role of Concomitant Diseases in Postoperative Complications Risk Stratification.","The Role of Concomitant Diseases in Postoperative Complications Risk Stratification - a Prospective Observational Multi-center Cohort Study","STOPRISK","Inclusion Criteria:\n\n* surgical interventions on the abdominal organs,\n* 1-3 ASA physical status class\n\nExclusion Criteria:\n\n* the inability to assess the factors included in the study,\n* acute massive blood loss, aspiration,\n* bronchospasm,\n* anaphylactic reactions,\n* malignant hyperthermia",{"count":585,"type":19},16000,"Study is conducted to assess the prevalence and structure of comorbidity among patients undergoing abdominal surgery and produce the stratification of the risk of postoperative complications by identifying independent predictors for its development.",[25,588,589,590,591,592,593,594,595,596,597,598,599],"Anemia","Bronchial Asthma","Stroke","Epilepsy","Parkinson's Disease","Heart Rhythm Disorders","Alzheimer's Disease","Neuromuscular Diseases","Diabetes","Chronic Heart Failure","Chronic Obstructive Pulmonary Disease","Chronic Kidney Diseases",[601,602,603],"anesthesia","concomitant diseases","risk stratification","2025-04-01",{"date":606,"type":31},"2025-04-04",{"date":608,"type":31},"2019-07-01",{"date":610,"type":19},"2026-02-28",{"name":612,"class":38},"Russian Federation of Anesthesiologists and Reanimatologists",38,{"id":615,"slug":616,"hasResults":12,"nctId":617,"briefTitle":618,"officialTitle":619,"acronym":4,"eligibilityCriteria":620,"healthyVolunteers":12,"sex":16,"minAge":47,"maxAge":330,"enrollmentInfo":621,"targetDuration":4,"studyType":75,"phases":623,"briefSummary":625,"conditions":626,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":628,"lastUpdatePostDateStruct":629,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":635,"locationsCount":637},"100552424","phase-3-efficacy-and-safety-of-colchicine-after-pci-100552424","NCT06472908","Efficacy and Safety of Colchicine After PCI","Efficacy and Safety of Colchicine After Percutaneous Coronary Intervention","Inclusion Criteria:\n\n* (1) Capable and willing to provide informed consent;\n* (2) Age ≥18 and ≤80 years old, regardless of sex;\n* (3) Hospitalized patients with CHD requiring PCI;\n* (4) Completion of all planned PCI during hospitalization;\n* (5) Standardized treatment of coronary artery disease according to national guidelines.\n\nExclusion Criteria:\n\n* (1) Known allergy to colchicine;\n* (2) Colchicine taken within 10 days prior to randomization group;\n* (3) Patients currently in cardiogenic shock or hemodynamically unstable;\n* (4) Patients with known inflammatory bowel disease or chronic diarrhea;\n* (5) Abnormal liver function (ALT\\> 3 times the upper limit of normal);\n* (6) Abnormal renal function (eGFR\\\u003C30mL\u002Fmin\u002F1.73m2);\n* (7) Active malignant tumors reported in past medical history;\n* (8) Existing or planned treatment with other anti-inflammatory or immunosuppressive drugs;\n* (9) Pregnant women, lactating women or women of childbearing age who did not use effective contraceptives;\n* (10) Any other circumstances in which the investigator judges that the patient is not suitable to participate in the clinical trial.",{"count":622,"type":19},8862,[624],"PHASE3","Colchicine (0.5 mg\u002Fday) was recommended by the U.S. Food and Drug Administration in 2023 for the anti-inflammatory treatment of coronary heart disease (CHD). However, colchicine is still not approved for CHD treatment in China. There is no large-scale clinical evidence that colchicine can be used to treat Chinese patients with CHD. Considering the low body weight of the East Asian population, it is unclear whether the recommended standard dose (0.5 mg\u002Fday) is suitable for Chinese patients. Therefore, we need to further explore the effects of different doses of colchicine on the efficacy and safety of clinical endpoints in the Chinese population with CHD.\n\nThis study is a multicenter, prospective, randomized, controlled, double-blind, event-driven clinical study conducted in China. The primary objective of this study is to determine whether long-term treatment with different doses of colchicine reduces the incidence of cardiovascular events in Chinese patients undergoing PCI. The secondary objective is to determine the safety of long-term treatment with different doses of colchicine in this patient population.",[25,312,627],"Colchicine","2025-03-25",{"date":630,"type":31},"2025-03-30",{"date":632,"type":31},"2024-07-09",{"date":634,"type":19},"2028-08-31",{"name":636,"class":38},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",36,{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":644,"eligibilityCriteria":645,"healthyVolunteers":135,"sex":16,"minAge":646,"maxAge":4,"enrollmentInfo":647,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":649,"conditions":650,"keywords":665,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":671,"lastUpdatePostDateStruct":672,"startDateStruct":674,"completionDateStruct":676,"leadSponsor":678,"locationsCount":39},"100361552","empower-1-a-multi-site-clinical-cohort-research-study-to-reduce-health-inequality-100361552","NCT03987633","EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","EMPOWER-1: A Multi-site Clinical Cohort Study to Reduce Health Inequality: Identifying Ethnic Disparities in Treatment Failures for Medicines Prescribed to Treat Diseases That Cause Significant Mortality and Morbidity in the UK Population","EMPOWER","Inclusion Criteria:\n\n1. Patients or their relative\u002Ffamily member is diagnosed with the illness being investigated by this study.\n2. All NHS patients that are associated with a participating study site, but do not fall under the first bullet point above, may participate with a view that they may potentially contribute to a case control population in the research study.\n3. Subjects agree to:\n\n   1. Gift biological samples, i.e. saliva. Where practical, blood or other biological samples may be voluntarily provided by the patient.\n   2. Provide Consent for access to medical records.\n   3. Complete disease specific, quality of life, and study associated questionnaires.\n\nExclusion Criteria:\n\n1. Patient does not provide a valid consent for study participation.\n2. Patient is not registered with the NHS for care.\n3. Patient lacking capacity, who does not have an illness that is being specifically investigated by this clinical research study.\n4. Person lacks capacity and where the personal consultee has not advised that the Person may enrol, in accordance with the Mental Health Act 2005.","6 Years",{"count":648,"type":19},200000,"Health inequality and genetic disparity are a significant issue in the United Kingdom (UK).\n\nThis study focuses on diseases that are associated with significant morbidity and mortality in the UK, and specifically examines the extent and basis of treatment failure in different patient populations.\n\nThe vast majority of drug registration clinical trials have under-representation of ethnic minority populations. In addition, the wider Caucasian populations have reasonably different clinical characteristics to the population that participated in the drug licencing clinical trials. A consequence of this is that drugs are licensed for use in real-world general patient populations where the clinical trial results are simply not statistically significant to specifically demonstrate efficacy or safety in populations that were either absent or under-represented in the drug registration clinical trials. When these facts are considered alongside data that supports significant under-reporting of adverse events in the real-world setting within the UK (and globally, e.g the USA and Europe), it highlights that pharmacovigilance systems are unable to capture drug effectiveness and safety data in a manner that can reasonably assure appropriate prescribing in the wider patient populations.\n\nThis large real-world research study aims to identify whether commonly prescribed drugs are effective in treating illnesses that cause significant poor health and death in the different patient populations that represent the UK.\n\nThe goal of this study is to generate large quantitative data-sets that may inform clinical practice to reduce the existing health inequality and genetic disparity in the UK.",[651,25,264,490,489,652,653,654,598,85,655,599,656,657,658,591,659,660,661,662,663,664],"Atrial Fibrillation","Peripheral Arterial Disease","Stroke, Ischemic","Asthma","Cancer","Diabetes Mellitus","Dementia","Depression","Mental Health Disorder","Rheumatoid Arthritis","Blood Pressure","Breast Cancer Risk","Prostate Cancer","Lung Cancers",[666,667,668,669,670],"genetic disparity","health inequality","genetics","health outcomes","equality","2025-03-05",{"date":673,"type":31},"2025-03-10",{"date":675,"type":31},"2020-02-01",{"date":677,"type":19},"2030-02-01",{"name":679,"class":38},"Future Genetics Limited"]